Drug-induced respiratory disorders. Incidence, prevention and management

Drug Safety

Volumn 23, Issue 2, 2000, Pages 143-164

  Ben Noun, Liubov Louba ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b NONE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANOREXIGENIC AGENT; ANTIARRHYTHMIC AGENT; ANTIASTHMATIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE; CALCIUM ANTAGONIST; CARDIOVASCULAR AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DIAMORPHINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; GOLD; HORMONE; HYDROCHLOROTHIAZIDE; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLPHENIDATE; METHYSERGIDE; NITROFURANTOIN; OPIATE AGONIST; ORAL CONTRACEPTIVE AGENT; PENICILLAMINE; PSYCHOTROPIC AGENT; UNINDEXED DRUG; UTERUS SPASMOLYTIC AGENT;

ASTHMA; ATELECTASIS; BRONCHIECTASIS; BRONCHIOLITIS; COUGHING; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DYSPNEA; EMPHYSEMA; FIBROSING ALVEOLITIS; GOODPASTURE SYNDROME; HEMOPTYSIS; HUMAN; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS CELL CARCINOMA; LUNG ALVEOLUS PROTEINOSIS; LUNG CALCIFICATION; LUNG EDEMA; LUNG EMBOLISM; LUNG FIBROSIS; LUNG HEMORRHAGE; LUNG TOXICITY; NOSE SEPTUM PERFORATION; PLEURA EFFUSION; PNEUMOTHORAX; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; REVIEW;

EID: 0033854228     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200023020-00005     Document Type: Review

References (268)

1. 1. McNeill RS. Effect of a beta-adrenergic blocking agent, propranolol, on asthmatics. Lancet 1964; II: 1101-2
2. 2. Tattersfield AE, Harrison RN. Effect of beta-blocker therapy on airway function. Drugs 1983; 25 Suppl. 2: 227-31
3. 3. Lewis RV, Lofthouse C. Adverse reactions with beta-adreno-receptor blocking drugs: an update [abstract]. Drug Saf 1993; 9:272
4. 4. Dunn TL, Gerber MJ, Shen AS, et al. The effect of topical ophtalmic instillation of timolol and betaxol on lung function in asthmatic subjects. Am Rev Respir Dis 1986; 133: 264-8
5. 5. Graft D, Fowles J, McCoy CE, et al. Detection of beta-blocker use in people with asthma. Ann Allergy 1992; 69: 449-53
6. 6. Craig TJ. Drugs to be used with caution in patients with asthma. Am Fam Physician 1996; 54: 947-53
7. 7. Odeh M, Oliven A, Bassaan H. Timolol eye-drop-induced fatal bronchospasm in an asthmatic patient. J Fam Pract 1991; 32: 97-8
8. 8. Schoene RB, Abuan T, Ward RL, et al. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophtalmol 1984; 97: 86-92
9. 9. Harris LS, Grenstein SH, Bloom AF. Respiratory difficulties with betaxolol [letter]. Am J Ophtalmol 1986; 102-274
10. 10. Beta-adrenoreceptor-blocking agents. In: Reynolds JEF, editor. Martindale: the extra pharmacopoeia. 30th ed. London: The Pharmaceutical Press, 1993: 624
11. 11. Perrone MH, Barrett JA. Preclinical pharmacology of celiprolol: a cardioselective β-adrenergic antagonists and mild vasodilator. Am Heart J 1991; 121: 677-83
12. 12. Lamon KD. Clinical safety and efficacy of celiprolol. Am Heart J 1991; 121: 683-7
13. 13. Riddel KG, Shanks RG, Brogden RN. Celiprolol: a preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. Drugs 1987; 34: 438-58
14. 14. Doshan HD, Brown R, Applin WJ, et al. Effects of high doses of celiprolol in asthmatic patients. J Cardiovas Pharmacol 1986; 8 Suppl. 4: S109-S11
15. 15. Matthys H, Doshan HD, Ruhle KH. The bronchosparing effects of celiprolol, a new beta-1 alpha-2 receptor antagonist, on pulmonary function of propraolol sensitive asthmatics. J Clin Pharmacol 1985; 25: 354
16. 16. Milne RJ, Buckley MMT. Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease. Drugs; 1991; 41: 941-69
17. 17. Austen KF, Orange RP. Bronchial asthma: the possible role of the chemical mediators of immediate hypersensitivity in the pathogenesis of subacute chronic disease. Am Rev Respir Dis 1975; 112: 423-36
18. 18. Fleckenstein-Grun G, Fleckenstein A. CA dependent changes in coronary smooth muscle tone and the action of Ca compounds with special reference to Adalat. In: Lochner W, Braasch W, Kroberg G, editors. 2nd International Adalat Symposium. New York (NY): Springer Verlag, 1976: 66-75
19. 19. Fish JE, Norman PS. Effects of the calcium channel blocker, verapamil, on the asthmatic airway responses to muscarinic, histaminergic, and allergic stimuli. Am Rev Respir Dis 1986; 133: 73-4
20. 20. Setton I, Hirsh D, Pragier G, editors. Israel Drug Compendium: IDC 1995 Petach-Tikva, Israel: The Pharmaceutical Section Manufacturers Association of Israel, 1995: 387-9
21. 21. Russi E, Danta I, Ahmed T. Comparative modification of antigen-induced bronchoconstriction by the calcium antagonists, nifedipine and verapamil. Chest 1985; 88: 74-8
22. 22. Patel KR, Shama AL, Kerr W. The effects of inhaled verapamil on allergen-induced bronchoconstriction. Clin Allergy 1983; 13: 119-22
23. 23. Ben-Noun L. Acute asthma associated with sustained-release verapamil. Ann Pharmacother 1997; 31: 593-5
24. 24. Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988; 319: 1517-25
25. 25. Marre M, Hallab M, Billiard A, et al. Small doses of ramipril to reduce micro-albuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes. J Cardiovasc Pharmacol 1991; 18 Suppl. 2: 165-8
26. 26. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-63
27. 27. Cox JP, Duggan J, O'Boyle CA, et al. A double blind evaluation of captopril in elderly hypertensives. J Hypertens 1989; 7: 299-303
28. 28. Lacourciere Y, Poirier L, Provencher P, et al. Once vs twice daily administration of a fixed combination of captopril plus hydrochlorothiaside in essential hypertension: a double-blind crossover study in known responders to a standard combinations. Br J Clin Pharmacol 1991; 32: 115-9
29. 29. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin converting enzyme inhibitor therapy: a review of literature and pathophysiology. Ann Intern Med 1992; 117:234-42
30. 30. Visser LE, Stricker BHCH, Van der Velden J, et al. Angiotensin converting inhibitor associated cough: a population based case-control study. J Clin Epidemiol 1995; 48: 851-7
31. 31. Visser LE, Vlug AE, Van der Lei J, et al. Cough due to ACE inhibitors: a case control study using automated general practice data. Eur J Clin Pharmacol 1996; 49: 439-44
32. 32. Charlton V, Dolow S, Fidel J, et al. Reproducibility of angiotensin converting enzyme inhibitor induced cough: a double-blind randomised study. Br J Clin Pharmacol 1995; 39: 125-9
33. 33. Lunde H, Hedner T, Samuelsson O, et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitor. BMJ 1994; 308: 18-21
34. 34. Lefevre J, Poirier L, Lacourciere Y. Prospective trial on captopril-related cough. Ann Pharmacother 1992; 26: 161-4
35. 35. Holzgreve H. Safety profile of the combination of verapamil and trandolapril. J Hypertens 1997; 15 Suppl. 2: S51-S53
36. 36. Dossegger L, Nielsen T, Preston C, et al. Heart failure therapy with cilazapril: an overview. J Cardiovasc Pharmacol 1994; 24 Suppl. 3: S28-S41
37. 37. Rosenthal JR, Osowski U. Tolerability and efficacy of antihypertensive treatment with cilazapril in general practice. Cardiology 1996; 87: 54-9
38. 38. Szucs T, Scheeweiss A. Cilazapril: an overview of its efficacy and safety in hypertension. Cardiology 1992; 80: 34-41
39. 39. Kang PM, Landau AJ, Eberhardt RT, et al. Angiotensin II receptor antagonists: a new approach to blockage of the renin-angiotensin system. Am Heart J 1994; 127: 1388-401
40. 40. Allen TL, Gora-Harper ML. Cromolyn sodium for ACE inhibitor-induced cough. Ann Pharmacother 1997; 31: 773-5
41. 41. McEwan JR, Choudry NB, Fuller RW. The effects of sulindac on the abnormal cough reflex associated with dry cough. J Pharmacol Exp Ther 1990; 255: 161-4
42. 42. Gilchrist NL, Richards AM, March R, et al. Effect of sulindac on ACE inhibitor induced cough: randomised placebo-controlled double blind cross-over study. J Hum Hypertens 1989;3:451-5
43. 43. Fogari R, Zoppi A, Tettamanti F, et al. Effects of nifedipine and indomethacine on cough induced by angiotensin-converting enzyme inhibitors. J Cardiovas Pharmacol 1992; 19: 670-3
44. 44. Onson C. Delay in diagnosis and empiric treatment of angiotensin-converting enzyme inhibitor induced cough in office practice. Arch Fam Med 1995; 4: 525-8
45. 45. Pomari C, Turco P, Negro RD. Has theophylline a role in the cure and prevention of ACE-inhibitor related cough? Respiration 1989; 55: 119-21
46. 46. Cazzola M, Matera MG, Licardi G, et al. Theophylline in the inhibition of angiotensin-convertin enzyme inhibitor-induced cough. Respiration 1993; 60: 212-5
47. 47. Aldis WL. Cromolyn for cough due to angiotensin-converting enzyme inhibitor therapy. Chest 1991; 100: 1741-2
48. 48. Jayasuria PH. Sodium cromoglycate for AC inhibitor cough. Med J Aust 1992; 156:363-4
49. 49. Hargreaves MR, Benson MK. Inhaled sodium cromoglycate in angiotensin converting enzyme inhibitor cough. Lancet 1995 ; 345:13-6
50. 50. Martin WJ, Rosenow EC. Amiodarone pulmonary toxicity (part 1) Chest 1988; 93: 1067-75
51. 51. Kennedy J Jr I. Clinical aspects of amiodarone pulmonary toxicity. Clm Chest Med 1990; 11: 119-29
52. 52. Dean PJ, Groshart KD, Porterfield JG, et al. Amiodarone associated pulmonary toxicity. A clinical and pathological study of eleven cases. Am J Clin Pathol 1987; 87: 7-13
53. 53. Martin WJ. Mechanisms of amiodarone pulmonary toxicity. Clin Chest Med 1990; 11: 131-8
54. 54. Dimopulou I, Marathias K, Daganou M, et al. Low-dose amiodarone-related complications after cardiac operations. J Thorac Cardiovasc Surg 1997; 114: 31-7
55. 55. Marchlinski FE, Gansler TS, Waxman HL, et al. Amiodarone pulmonary toxicity. Ann Intern Med 1982 1982; 97: 839-45
56. 56. Rakita L, Sobol SM, Mostow N, et al. Amiodarone pulmonary toxicity. Am Heart J 1983; 106: 906-14
57. 57. Greenspon A, Kidwell GA, Hurley W, et al. Amiodarone-related postoperative adult respiratory distress syndrome. Circulation 1991; 84 Suppl. III: S407-S415
58. 58. Martin WJ, Rosenow EC. Amiodarone pulmonary toxicity. Recognition and pathogenesis (part 2). Chest 1988; 93: 1242-8
59. 59. Morady, Sauve MJ, Malone P, et al. Long-term efficacy and toxicity of high dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. Am J Cardiol 1983; 52: 975-9
60. 60. Heger JJ, Prystowsky EN, Jackman WM, et al. Amiodarone. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia and fibrillation. N Engl J Med 1981; 305: 539-45
61. 61. Totmensch HH, Siron M, Tupliski M, et al. Possible association of pneumonitis with amiodarone therapy. Am Heart J 1980; 100:412-3
62. 62. VanZadiok N, Darmata JI, Diiren DR, et al. Amiodarone pneumonitis. Eur J Respir Dis 1983; 64: 313-7
63. 63. Heger JJ, Prystowsky EN, Ziper DP. Relationship between amiodarone dosage drug concentrations and adverse side effects. Am Heart J 1983; 106:931-4
64. 64. Kowey PR, Friehling TD, Marinchak RA, et al. Safety and efficacy of amiodarone. The low-dose perspective. Chest 1988; 93: 54-5
65. 65. Zaher C, Hamer A, Peter I, et al. Low dose steroid therapy for prophylaxis of amiodarone-induced pulmonary infiltrates. N Engl J Med 1983; 308: 779
66. 66. Horn HR, Hadidian Z, Johnson JL, et al. Safety evaluation of tocainide in the American emergency use program. Am Heart J 1980; 100: 1037-40
67. 67. Holmes B, Heel RC. Flecainide: a preliminary report of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985; 29: 1-33
68. 68. Feinberg L, Travis WD, Ferrans V, et al. Pulmonary fibrosis associated with tocainide. Am Rev Respir Dis 1990; 141: 505-8
69. 69. Hanston P, Evrard P, Mahieu P, et al. Flecainide associated interstitial pneumonitis. Lancet 1991: 337: 371-2
70. 70. Akoun G, Cadranel JL, Israel-Biet D, et al. Flecainide-associated pneumonitis. Lancet 1991; 49: 337: 49
71. 71. Ranhovsky A, Kempthorne-Rawson J. The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Circulation 1990; 81: 1205-9
72. 72. Simon RS, Baldwin JL. Drug-induced asthma. In: Bierman CW, Pearlman DS, Shapiro GG, editors. Allergy, Asthma, and Immunology from Infancy to Adulthood. 3rd ed. Philadelphia (PA): WB Saunders, 1996: 549-57
73. 73. Biron P, Dessureault J, Napke E. Acute allergic interstitial pneumonitis induced by hydrochlorothiaside. Can Med Assoc J 1991; 145:28-34
74. 74. Kavaru MS, Ahmad M, Amirthalingam KN. Hydrochlorothiaside-induced acute pulmonary edema. Cleve Clin J Med 1990; 57: 181-4
75. 75. Bell RT, Lippmann M. Hydrochlorothiazide-induced pulmonary edema. Arch Intern Med 1979; 139: 817-9
76. 76. Steinberg AD. Pulmonary edema following ingestion of hydrochlorothiazide. JAMA 1968; 204: 825-7
77. 77. Dorn MR, Walker BK. Noncardiogenic pulmonary edema associated with hydrochlorothiazide therapy. Chest 1981; 79: 484-3
78. 78. 1 WW, Mulroy MF, Sandri SR. Pneumonitis and hydrochlorothiaside. Ann Intern Med 1973; 70: 293
79. 79. Bianco S, Vaghi A, Robuschi M, et al. Prevention of exercise-induced bronchoconstriction by inhaled frusemide. Lancet 1988; II: 252-5
80. 80. Bianco S, Pieroni MG, Refini RM, et al. Protective effect of inhaled furosemide on allergen-induced early and late asthmatic reactions. N Engl J Med 1989; 321: 1069-73
81. 81. Anonymous. Inhaled furosemide and asthma. Lancet 1990; 335: 944-6
82. 82. Anderson SD, Wei HE, Temple DM, et al. Inhibition by furosemide of inflammatory mediators from lung fragments. N Engl J Med 1991; 324: 131
83. 83. Lloyd EL. Frusemide and prevention of bronchoconstriction. Lancet 1988; II: 564
84. 84. Chung KF, Barnes PJ. Inhaled frusemide on bronchial responsiveness to methacholine. N Engl J Med 1990; 322: 935-6
85. 85. Flower RF, Moncada S, Vane JR. Drug therapy of inflammation. Analgesic antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout. In: Gilman AG, Goodman LS, Rall TW, et al., editors. The pharmacological basis of therapeutics. 7th ed. New York (NY): MacMillan, 1985: 686-8
86. 86. Falliers CJ. Aspirin and subtypes of asthma: risk factors. J Allergy 1973; 52: 141-7
87. 87. Vedanthan PK, Menon MM, Bell TD, et all. Aspirin and tartrazine oral challenge: incidence of adverse response in chronic childhood asthma. J Allergy Clin Immunol 1977; 60: 8-13
88. 88. Rachelevsky GS, Coulson A, Siegel SC, et al. Aspirin intolerance in chronic asthma detected by oral challenge. Pediatrics 1975; 56: 443-8
89. 89. Szczeklik A, Grylewski RJ. Asthma and antiinflammatory drugs: mechanisms and clinical patterns. Drugs 1983; 25: 533-43
90. 90. VanLeeuwen WS. Pathognomonishe bedeutung der Uebermpfindlichkeit gegen Aspirin bei Asthmatikern. Munch Med Wochenschr 1928; 75: 1588
91. 91. McDonald JR, Mathison DA, Stevenson DD. Aspirin intolerance in asthma. J Allergy Clin Immunol 1972; 50: 198-207
92. 92. Farr RS. The need to re-evaluate acetylsalicylic acid (aspirin). J Allergy 1970; 45: 321-8
93. 93. Stenius BSM, Lemola M. Hypersensitivity to acetylsalicylic acid (ASA) and tartrazine in patients with asthma. Clin Allergy 1976; 6: 119-29
94. 94. Farr RS, Spector SL, Wangaard C. Asthma and non-steroidal antiinflammatory drugs. Ann Intern Med 1978; 89: 577-600
95. 95. Samter M, Beers Jr RF. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med 1968; 68: 975-83
96. 96. Lockey RF, Rucknagel DL, Vanselow NA. Familial occurrence of asthma, nasal polyposis and aspirin intolerance. Ann Intern Med 1973; 78: 57-63
97. 97. Settipane GA, Puddupakkam RK. Aspirin intolerance III: subtypes, familial occurrence, and cross-reactivity with tartrazine. J Allergy Clin Immunol 1975; 56: 215-21
98. 98. Dahlen BM, Kumlin DM, Margolskee C, et al. The leukotriene receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993; 6: 1018-26
99. 99. Lee TH. Mechanisms of bronchospasm in aspirin-sensitive asthma. Am Rev Respir Dis 1993; 148: 1442-3
100. 100. Szczeklik A, Gryglewski RJ, Czerniavska-Mysik G, et al. Aspirin induced asthma: hypersensitivity to fenoprofen and ibuprofen in relation to their inhibitory action to prostaglandin generation by different microsomal enzymic preparations. J Allergy Clin Immunol 1976; 58: 10-8
101. 101. Santiago Jr SM. Acute respiratory failure secondary to indomethacin in an aspirin intolerant asthmatic patient. Ann Allergy 1976; 37: 138-41
102. 102. Polachek J, Shvartzman P. Acute bronchial asthma associated with the administration of ophtalmic indomethacin Isr J Med Sci 1996; 32: 1107-9
103. 103. Sitenga GL, Yong ER, Van Dellen RG, et al. Asthma caused by topical application of ketorolac. Ophtalmology 1996; 103:890-2
104. 104. Goldin J, Hayhurst M, Potgieter PD. Severe asthma due to intravenous avapyrazone and dipyrone [letter]. S Afr Med J 1986; 69: 162
105. 105. Timperman JA. A fatal asthmatic attack following administration of an indomethacin suppository. J Forensic Med 1971; 98: 30-2
106. 106. Herbert WG, Scopelitis E. Ketorolac-precipitated asthma. South Med J 1994; 87: 282-4
107. 107. Hume M, Eddy V. Treatment of chronic obstructive airways obstruction with indomethacin. Scan J Respir Dis 1977: 58: 284-6
108. 108. Nishikawa M, Yoshinaga T, Igarashi A, et al. Clinical experience with indomethacin (Indacin). Shiryo-To-Shiyaku 1966; 3: 1917-20
109. 109. Kordansky D, Adkinson F, Norman PS, et al. Asthma improved by nonsteroidal anti-inflammatory drugs. Ann Intern Med 1978; 88: 508-11
110. 110. Jackson RH, Raymer WJ, Etter RL. New therapy in bronchial asthma: an evaluation of Ponstel (mefanic acid) in chronic bronchial asthma and pulmonary emphysema. J Kansas Med Soc 1969; 69: 474-8
111. 111. Herxheimer H, Stresseman E. Anti-asthmatic effect of phenazone and amidopyrine. Nature 1961; 192: 1089-90
112. 112. Hady S. Dipyrone in bronchial asthma [letter]. BMJ 1973; 1: 744
113. 113. Streseman E. Die Wirkung von antipyretischen and analgetischensubstanzen auf das menschliche bronchial asthma und das experimentelle Meerschweiche asthma. Acta Allergologica 1963; 18: 211-34
114. 114. Azelastine-Asthma study group. An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. J Allergy Clin Immunol 1996; 97: 1218-24
115. 115. Ben-Noun L. Drug-related asthma. J Pharm Technol 1998; 14: 116-24
116. 116. Sweet JM, Stevenson DD, Simon RA, et al. Long-term effects of aspirin desensitization-treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol 1990; 85 (Pt 1): 59-65
117. 117. Szczeklik A, Mastalerz L, Nizakowska E, et al. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med 1996; 153: 567-71
118. 118. Seth RV, Clarke VS, Lewis RA, et al. Effect of propranolol on the airway response to prostaglandin E2 in normal man. Br J Clin Pharmacol 1981; 12: 731-5
119. 2-agonists : greater protection against adenosine monophosphate than metacholine -induced bronchoconstriction in asthma. Am J Respir Crit Med 1994; 150: 381-7
120. 120. Szczeklik A. Aspirin-induced asthma. In: Vane JR, Botting RM, editors. Aspirin and other salicylates. New York (NY): Chapman & Hall Medical, 1992: 548-75
121. 121. Sladek KR, Dworski J, Soja JR, et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994; 149: 940-6
122. 122. Josefson D. Asthma linked with Churg-Strauss syndrome [letter]. BMJ 1997; 315: 330
123. 123. Christie PE, Smith CM, Lee TH. The potent and selective sulidopeptide leukotriene antagonists, SK and F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144: 957-8
124. 124. Dahl R. Oral and inhaled sodium cromoglycate in challenge test with food allergens or acetylsalicylic acid. Allergy 1981; 36: 161-5
125. 125. Israel EA, Fischer MA, Rosenberg CM, et al. The pivotal role of lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447-51
126. 126. Szczeklik A, Serwonska M. Inhibition of idiosyncratic reactions to aspirin in asthmatic patients by clemastine. Thorax 1979; 34: 654-7
127. 127. Philips GD, Foord R, Holgate ST. Inhaled lysine-aspirin as a bronchoprovocation procedure in aspirin-induced asthma: its repeatability, absence of late-phase reaction and the role of histamine. J Allergy Clin Immunol 1989; 84: 323-41
128. 128. O'Byrne M. Leukotrienes in the pathogenesis of asthma. Chest 1997; 111: S27-S34
129. 129. Spector SL, Wangaard CH, Farr RS. Aspirin and concomitant idiosyncrasies in the adult asthmatic patients. J Allergy Clin Immunol 1979; 64: 500-6
130. 130. Lipworth BJ. The emerging role of leukotriene antagonists in asthma therapy. Chest 1999; 115: 313-5
131. 131. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist in the treatment of chronic asthma. Arch Int Med 1998; 158: 123-20
132. 132. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6-to 14-year oldchildren with asthma. J Pediatr 1998; 133: 424-8
133. 133. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone and placebo for chronic asthma. Ann Intern Med 1999; 130: 487-95
134. 134. Masi At, Hunder GG, Lie JT, et al. The American Colledge of Rheumatology 1990 criteria for the classification of the Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33; 1094-100
135. 135. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279: 455-7
136. 136. Knoell DL, Lucas J, Allen JN. Churg-Strauss syndrome associated with zafirlukast. Chest 1998; 114: 332-4
137. 137. Flower RJ, Moncada S, Vane JR. Analgetic-antipyretic and anti-inflammatory agents; drugs employed in the treatment of gout. In: Gilman AG, Goodman LS, Gilman A, editors. The pharmacological basis of therapeutics. 6th ed. New York (NY): MacMillan, 1980: 682-728
138. 138. Rosenow EC III. Drug-induced pulmonary disease. In: Murray JF, Nadel JA, editors. Textbook of respiratory medicine. Philadelphia (PA): WB Saunders, 1994: 2117-43
139. 139. Smith W, Ball GV. Lung injury due to gold treatment. Arthritis Rheum 1980; 23: 351-4
140. 140. Scott DL, Bradgy GVH, Altman TJ, et al. Relationship of gold and penicillamine therapy to diffuse interstitial lung disease. Ann Rheum Dis 1981; 40: 136-41
141. 141. Ettensohn DB, Roberts NJ, Condemi JJ. Bronchoalveolar lavage in gold lung. Chest 1984; 85: 569-70
142. 142. Klassen CD. Heavy metals and heavy-metal antagonists. In: Gilman AG, Goodman LS, Gilman A, editors. The pharmacological basis of therapeutics. 6th ed. New York (NY): Macmillan, 1980: 1615-37
143. 143. Stein HB, Patterson AC, Offer RC, et al. Adverse effects of d-penicillamine in rheumatoid arthritis. Ann Intern Med 1980; 92: 24-9
144. 144. Lyle WH. D-Penicillamine and fatal obliterative bronchiolitis. BMJ 1977; 1: 105
145. 145. Chalmes A, Thompson D, Stein HB, et al. Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis. Ann Intern Med 1982; 97: 659-63
146. 146. Cooper JAD, White DA, Matthay RA. Drug-induced pulmonary disease. Part 2: noncytotoxic drugs. Am Rev Respir Dis 1986; 133: 488-505
147. 147. Holmberg L, Boman G, Bottiger LE, et al. Adverse reactions to nitrofurantoin. Analysis of 921 reports. Am J Med 1980; 69; 733-8
148. 148. Hailey FJ, Glascock HW, Hewitt WF. Pleuropneumonic reactions to nitrofurantoin. N Engl J Med 1969; 282: 1087-90
149. 149. Rosenow EC, Martin WJ. Drug-induced interstitial lung disease. In: Schwarz MI, King Jr TE, editors. Interstitial lung disease. Toronto: BC Decker, 1988: 123-37
150. 150. Prakash UBS. Pulmonary reaction to nitrofurantoin. Semin Respir Dis 1980; 2: 71-5
151. 151. Holmberg L, Boman G. Pulmonary reactions to nitrofurantoin. 447 cases reported to the Swedish Adverse Drug Reaction Committee 1966-1976. Eur J Respir Dis 1981; 62: 180-9
152. 152. Dweik RA. Drug-induced pulmonary disease. In: Baum GL, Crapo JD, Celli BR, et al., editors. Textbook of pulmonary diseases. 6th ed. Philadelphia (PA): Lippincott Raven, 1988: 477-90
153. 153. Wang KK, Bowyer BA, Fleming CR, et al. Pulmonary infiltrates and eosinophilia associated with sulphasalazine. Mayo Clin Proc 1984; 59: 343-6
154. 154. Jordan A, Cowan RE. Reversible pulmonary disease and eosinophilia associated with sulphasalazine. J R Soc Med 1988; 81: 233-5
155. 155. Williams T, Eidus L, Thomas P. Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy. Chest 1982; 81: 766-8
156. 156. Warner WA, Sanders E. Neuromuscular blockage associated with gentamicin therapy. JAMA 1971; 215: 1153-4
157. 157. Dutcher JP, Kendall J, Norris D, et al. Granulocyte transfusion therapy and amphotericin B. Am J Hematol 1989; 31: 102-8
158. 158. Levine SJ, Walsh TJ, Martinez A, et al. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med 1991; 114: 664-6
159. 159. Roncoroni AJ, Corrado C, Besuchio SB, et al. Bronchiolitis obliterans possibly associated with amphotericin [letter]. B J Infect Dis 1990; 161:589
160. 160. Geahart MO, Bhutani MS. Intravenous pentamidine-induced bronchospasm. Chest 1992; 102: 1891-2
161. 161. Katzman M, Meade W, Iglar K, et al. High incidence of bronchospasm with regular administration of aerolized pentamidine. Chest 1992; 101: 79-81
162. 162. McFadden ER. Obstructive lung disease: anticholinergic agents. In: Branch WT, editor. Office practice of medicine. Philadelphia (PA): WB Saunders, 1987: 315-29
163. 163. Patel KR, Tullet WM. Bronchoconstriction in response to ipratropium bromide. BMJ 1983; 286: 1318
164. 164. Beasley CRW, Rafferty P, Holgate ST. Bronchoconstriction properties of preservatives in ipratropium bromide (Aerovent) nebulised solution. BMJ 1987; 294: 1197-8
165. 165. Connolly CK. Adverse reaction to ipratropium bromide. BMJ 1982; 294: 1197-8
166. 166. Clark RJ. Exacerbation of asthma after nebulised beclamethasone diproprionate. Lancet 1986; I: 74-5
167. 167. McGivern DV, McFarlane JT. Severe bronchoconstriction after inhalation of budenoside. BMJ 1984; 288: 447
168. 168. Shim C, Williams Jr MH. Cough and wheezing from beclamethasone aerosol. Chest 1987; 91: 207-9
169. 169. Kounis NG. Untoward reaction to corticosteroids: intolerance to hydrocortisone. Ann Allergy 1976; 36: 203-6
170. 170. Dajani JC, Sliman NA, Shubar KS, et al. Bronchospasm caused by intravenous hydrocortisone sodium succinate (SoluCortef) in aspirin sensitive asthmatics. J Allergy Clin Immunol 1981; 68: 201-4
171. 171. Partrige MR, Gibson GL. Adverse bronchial reaction to intravenous hydrocortisone in aspirin-sensitive patients. BMJ 1978; 1: 1521-2
172. 172. Prophylactic anti-asthma agents. In: Reynolds JEF, editor. Martindale: the extra pharacopoeia. 30th ed. London: The Pharmaceutical Press, 1993: 1140-6
173. 173. Ibanex MD, Laso T, Irineo MM-S, et al. Anaphylaxis to disodium cromoglycate. Ann Allergy Immunol 1996; 77: 185-6
174. 174. Murphy S, Kelly HW. Cromolyn sodium: a review of mechanisms and clinical use in asthma. Drug Intell Clin Pharm 1987; 21: 22-35
175. 175. Serup J. Severe asthmatic reaction during long-term treatment with disodium cromoglycate powder inhalations. Acta Med Scand 1979; 205: 447-8
176. 176. Leynadier F, Pujade-Lauraine MD, Cornaille G. Death after cromoglycate. Allergy 1985; 40: 540-1
177. 177. Sheffer AL, Rocklin RE, Goetzi EJ. Immunologic component of hypersensitivity reactions to cromolyn-sodium. N Engl J Med 1975; 293: 1220-4
178. 178. Settipane GA, Klein DE, Boyd GK, et al. Adverse reactions to cromolyn. JAMA 1979; 23: 811-3
179. 179. Skarpaas IJK. An unexpected reaction towards disodium chromoglycate. Allergy 1987; 42: 318-9
180. 180. Brown LA, Kaplan RA, Benjamin PA, et al. Immunoglobulin E-mediated anaphylaxis with inhaled cromolyn sodium. J Allergy Immunol 1989; 68: 416-20
181. 181. Wass U, Plaschke P, Bjorkander J, et al. Assay of specific IgE antibodies to disodium cromoglycate in serum from patients with an immediate hypersensitivity reactions. J Allergy Clin Immunol 1988; 81: 752-7
182. 182. Allegra L, Bianco S. Non-specific bronchoreactivity obtained with an ultrasonic aerosol of d stilled water. Eur J Respir Dis 1980; 61 Suppl.: S41-S49
183. 183. Sheppard D, Rizk N, Boushey HA, et al. Mechanism of cough and bronchoconstriction induced by distilled water aerosol. Am Rev Respir Dis 1983; 127: 691-4
184. 184. Schoeffel RE, Anderson SD, Altounyan RE. Bronchial hyperreactivity in response to inhalation of ultrasonically nebulized solutions of distilled water and saline. BMJ 1981; 283: 1285-7
185. 185. Nicklas RA. Paradoxical bronchospasm associated with the use of inhaled beta agonists. J Allergy Clin Immunol 1990; 85 : 959-64
186. 186. Graff-Lonnevig V. Diurnal expiratory flow after inhalation of Freons and fenoterol in childhood asthma. J Allergy Clin Immunol 1979; 64: 534-8
187. 187. Sterline GM, Batten JC. Effect of aerosol propellants and surfuctants on airway resistance. Thorax 1969; 24: 226
188. 188. Valic F, Skuvic Z, Bantic Z, et al. Effects of fluorocarbone propellants on respiratory airflow and ECG. Br J Ind Med 1977; 34: 130
189. 189. Gong Jr H, Tashkin DP, Calvarese BM. Alcohol-induced bronchospasm in an asthmatic patient: pharmacological evaluation of the mechanism. Chest 1981; 80: 167-73
190. 190. Stevenson DD, Simon RA. Sulfites and asthma. J Allergy Clin Immunol 1984; 74: 469-72
191. 191. Schwartz HJ, Chester EH. Bronchospastic responses to aerosolised metabisulphite in asthmatic subjects: potential mechanisms and clinical implications. J Allergy Clin Immunol 1984; 74: 511-3
192. 192. Anonymous. Nebulisers and paradoxical bronchoconstriction [letter]. Lancet 1988; II: 202
193. 193. Cooper JAD, White DA, Matthay RA. State of the art. Drug induced pulmonary disease. Part I: Cytotoxic drugs. Am Rev Resp Dis 1986; 133: 321-40
194. 194. Rosenow EC, Wilson WR, Cockerill FR. Pulmonary disease in the immunocomprised host. Mayo Clin Proc 1985; 60: 473-87
195. 195. Holoye PY, Luna MA, MacKay B, et al. Bleomycin hypersensitivity pneumonitis. Ann Intern Med 1978; 88: 47-9
196. 196. Twohig KL, Mattay RA. Pulmonary effects of cytotoxic agents other than bleomycin. Clin Chest Med 1990; 11: 31-54
197. 197. O'Driscoll BR, Hasleton PS, Taylor PM, et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 1990; 323: 378-82
198. 198. SelkerRG, Jacobs SA, Moore PB, et al. 1,3-Bis(2-chloroethyl) -1-nitrosourea (BCNU)-induced pulmonary fibrosis. Neurosurgery 1980; 7: 760-5
199. 199. Weiss RB, Poster DS, Penta JS. The nitrosoureas and pulmonary toxicity. Cancer Treat Rev 1981; 8: 111-25
200. 200. Pascual RS, Mosher MB, Sikand RS, et al. Effects of bleomycin on pulmonary function in man. Am Rev Respir Dis 1975; 108: 211-7
201. 201. Ahlgren JD, Smith FP, Kervin DM, et al. Pulmonary disease as a complication of chlorozotocin chemotherapy. Cancer Treat Rep 1981; 65: 223-9
202. 202. Yagoda A, Mukherji B, Young C, et al. Bleomycin: an antitumor antibiotic: clinical experience in 274 patients. Ann Intern Med 1972; 77: 861-70
203. 203. Brashear RE. Effects of heroin, morphine, methadone, and propoxyphene on the lung. Semin Respir Med 1980; 2: 59-69
204. 204. Heffner JE, Harley RA, Schabel SI. Pulmonary reactions from illicit substance abuse. Clin Chest Med 1990; 11: 151-62
205. 205. Overland ES, Nolan AJ, Hopewell PC. Alternation of pulmonary function in intravenous drug abusers: prevalence, severity, and characterization of gas exchange abnormalities. Am J Med 1980; 68: 231-7
206. 206. Smith WR, Wells JD, Glauser FL, et al. Immunologic abnormalities in heroin lungs. Chest 1975; 68: 651-3
207. 207. O'Donnell AE, Pappas LS. Pulmonary complications of intravenous drug abuse. Experience at an inner-city hospital Chest 1988; 94: 251-3
208. 208. Ettinger L, Albin RJ. A review of the respiratory effects of smoking cocaine. Am J Med 1989; 87: 664-8
209. 209. McCarrol KA, Roszler MH. Lung disorders due to drug abuse. J Thorac Imaging 1991; 6: 30-5
210. 210. Kline JN, Hirasuna JD. Pulmonary edema after free-base cocaine smoking not due to an adulterant. Chest 1990; 97: 1009-10
211. 211. Patel RC, Dutta D, Schonfeld SA. Free-base cocaine use associated with bronchiolitis obliterans organizing pneumonia. Ann Intern Med 1987; 107: 186-7
212. 212. Collins E, Hardwick H, Jeffery H. Perinatal cause of cocaine intoxication. Med J Aust 1989; 150: 331-2.
213. 213. Rubin RB, Neugarten J. Cocaine-associated asthma. Am J Med 1990; 88: 438-9
214. 214. Forrester JM, Steele AW, Waldron JA. Crack lung: an acute pulmonary syndrome with a spectrum of clinical and histological findings. Am Rev Respir Dis 1990; 142; 462-7
215. 215. Franz DN. Central nervous system stimulants. In: Gilman AG, Goodman LS, Rall TW, et al., editors. The pharmacological basis of therapeutics. 7th ed. New York (NY): Macmillan, 1985: 586-7
216. 216. Parran Jr TV, Jasinski DR. Intravenous methylphenidate abuse. Arch Intern Med 1991; 151: 781-3
217. 217. Schmidt RA, Glenny RW, Godwin ID, et al. Panlobular emphysema in young intravenous ritalin abusers. Am Rew Respir Dis 1991; 143: 649-56
218. 218. Mahutte CK, Nakasato SK, Light RW. Haloperidol and sudden death due to pulmonary edema. Arch Intern Med 1982; 142: 1951-2
219. 219. Li C, Gefter WB. Acute pulmonary edema induced by overdosage of phenothiazines. Chest 1992; 101: 102-4
220. 220. Roy TM, Ossorio MA, Cipola LM, et al. Pulmonary complications of tricyclic antidepressant overdosage. Chest 1989; 96: 852-6
221. 221. Varnell RM, Godwin JD, Richardson ML, et al. Adult respiratory distress syndrome from overdose of tricyclic antidepressants. Radiology 1989; 170: 667-70
222. 222. Shannon M, Lovejoy Jr FH. Pulmonary consequences of severe tricyclic anti-depressant ingestion. J Toxicol Clin Toxicol 1989; 25: 443-61
223. 223. Wilson IC, Gambill JM, Sandifer MG. Loefler's syndrome occurring during imipramine therapy. Am J Psychiatry 1963; 119: 892-3
224. 224. Cullinan SA, Bower GC. Acute pulmonary hypersensitivity to carbamazepine. Chest 1975; 68: 580-1
225. 225. Stephan WC, Parks RD, Tempest B. Acute hypersensitivity pneumonitis associated with carbamazepine therapy. Chest 1978; 74: 463-4
226. 226. Ingemarsson I, Arulkumaran S, Kottegota SR. Complications of beta-mimetic therapy in preterm labour. Aust N Z J Obstet Gynaecol 1985; 25: 182-9
227. 227. Reed CR, Glauser FL. Drug-induced noncardiogenic pulmonary edema. Chest 1991; 100: 1120-4
228. 228. Pisani RJ, Rosenow EC. Pulmonary edema associated with tocolytic therapy. Ann Intern Med 1989; 110: 714-8
229. 229. Eliasson O, Scherzer HH, DeGraff AC. Morbidity in asthma in relation to menstrual cycle. J Allergy Clin Immunol 1986; 77: 87-94
230. 230. Gibs CJ, Coutts II, Lock R, et al. Premenstrual exacerbation of asthma. Thorax 1984; 39: 833-6
231. 231. Derimanov G, Oppenheimer I. Exacerbation of premenstrual asthma caused by oral contraceptive. Ann Allergy Asthma Immunol 1998; 82: 243-6
232. 232. Tan KS, McFarlane LC, Lipworth BJ. Paradoxical down-regulation and desensitization of beta 2-adrenoreceptors by exogenous progesterone in female asthmatics. Chest 1997; 111: 847-51
233. 233. Tan KS, McFalane LC, Lipworth BJ. Loss of normal cyclical beta 2-adrenoreceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. Thorax 1997; 52: 608-11
234. 234. Tan KS, McFarlane LC, Lipworth BJ. Modulation of airway reactivity and peak flow variability in asthmatics receiving the oral contraceptive pill. Am J Respir Crit Care Med 1997; 155: 1273-7
235. 235. Troisi RJ, Speizer FE, Willett WC, et al. Menopause, postmenopausal estrogen preparations, and the risk of adult onset asthma. Am J Respir Crit Care Med 1995; 152: 1183-8
236. 236. Kinnunen E, Viljanen A. Pleuropulmonary involvement during bromocriptine treatment. Chest 1988; 94: 1034-3
237. 237. McElvaney NG, Wilcox PG, Churg A, et al. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med 1988; 148: 2231-6
238. 238. Hindle W, Posner E, Sweetnam MMT, et al. Pleural effusion and fibrosis during treatment with methysergine. BMJ 1970; 6: 83-102
239. 239. Rubin LJ. Primary pulmonary hypertension. Chest 1993; 104: 236-50
240. 240. Rich S, Danzker DR, Ayrer SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216-23
241. 241. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-16
242. 242. Hadengue A, Benhayoun MK, Lebree D, et al. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100: 520-8
243. 243. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983; 127: 437-41
244. 244. Kleiger RE, Boxer M, Ingham RE, et al. Pulmonary hypertension in patients using oral contraceptives: a report of six cases. Chest 1976; 69: 143-7
245. 245. Masi AT. Pulmonary hypertension and oral contraceptive usage. Chest 1976; 69: 451-3
246. 246. Legoux B, Piette AM, Boucher PE, et al. Pulmonary hypertension and HIV infection. Am J Med 1990; 89: 122
247. 247. Londino A Jr V, Wolf GL, Calabro JJ, et al. Naproxen and pneumonitis [letter]. JAMA 1984; 252: 1853
248. 248. Antineoplastic agents and immunosuppressants. In: Reynolds JEF, editor. Martindale: the extra pharmacopoeia. 30th edition. London: The Pharmaceutical Press, 1993: 434-507
249. 249. Cherniac RM, Abrams J, Kalica AR. Pulmonary disease associated with breast cancer therapy. J Respir Crit Care Med 1994; 150: 1169-73
250. 250. Cohen MB, Austin JHM, Smith-Vaniz A, et al. Single case reports. Nodular bleomycin toxicity. Am J Clin Pathol 1989; 92: 101-4
251. 251. Santrach PL, Askin FB, Wells RJ, et al. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer 1989; 64: 806-11
252. 252. Rao SX, Ramaswamy G, Levin M, et al. Fatal acute respiratory failure after vinblastine-mitomycin therapy in lung carcinoma. Arch Intern Med 1985; 145: 1906-7
253. 253. Hoelzer KL, Harrison BR, Luedke SW, et al. Vinblastine-associated pulmonary toxicity in patients receiving combination therapy with mitomycin and cisplatin. Drug Intell Clin Pharm 1986; 20: 287-9
254. 254. Bellamy EA, Husband JE, Blaquiere RM, et al. Bleomycin-related lung damage: CT evidence. Radiology 1985; 156:155-8
255. 255. Min K-W, Gyorkey FI. Interstitial pulmonary fibrosis, atypical epithelial changes and bronchiolar cell carcinoma following busulfan therapy. Cancer 1968; 22: 1027-32
256. 256. Aymard JP, Gyger M, Lavallee R, et al. A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia. A peculiar pathologic aspect of busulfan lung? Cancer 1984; 53: 954-6
257. 257. Sostman HD, Matthay RA, Putman CE. Cytotoxic drug-induced lung disease. Am J Med 1977; 62: 608-15
258. 258. Durant JR, Norgard MJ, Murad TM, et al. Pulmonary toxicity associated with bischloroethyl nitrosourea (BCNU). Ann Intern Med 1979; 90: 191-4
259. 259. Kuplic JB, Higley CS, Niewoehner DE. Pulmonary ossification associated with long-term busulfan therapy in chronic myeloid leukemia. Am Rev Respir Dis 1972; 106: 759-62
260. 260. Stolley PD, Tonascia JA, Tockman MS, et al. Thrombosis with low-estrogen oral contraceptives. Am J Epidemiol 1975; 102: 197-208
261. 261. Wright DG, Robichaud KJ, Pizzo PA, et al. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 1981; 304: 1185-9
262. 262. Davies D, MacFarlane A. Fibrosing alveolitis and treatment with sulphasalazine. Gut 1974; 15: 185-8
263. 263. Tydd TF, Dyer NH. Sulphasalazine lung. Med J Aust 1976; 1: 570-1
264. 264. Sternlieb I, Bennet B, Scheinberg IH. D-penicillamine induced Goodpasture's syndrome in Wilson's disease. Ann Intern Med 1975; 82: 673-6
265. 265. Shesser R, Davis C, Edeldtein S. Pneumomediastinum and pneumothorax after inhaling alkyloid cocaine. Ann Emerg Med 1982; 10: 213-5
266. 266. Morris JB, Shock JM. Pneumomediastinum in a young male cocaine user. Ann Emerg Med 1985; 14: 264-6
267. 267. Murray JB, Smialek J, Golle M, et al. Pulmonary vascular abnormalities in cocaine users. Am Rev Respir Dis 1988; 137 Suppl. 4 (Pt 22): 459
268. 268. Alfred RJ, Ewer S. Fatal pulmonary edema following intravenous 'freebase' cocaine use. Ann Emerg Med 1981; 10: 441-2